Investigational drug · Phase 3
DLBS3233
Also called: Inlacin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prediabetes.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
6
Any phase or sponsor naming "DLBS3233"
First trial start
2025
Jul 7, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DLBS3233", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prediabetes
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "DLBS3233" as an intervention, largest first.
- PCOS Treatment Using DLBS3233, Metformin, and Combination of BothPivotal-lookingCompleted
Dexa Medica GroupIndustry
NCT01999686 · 186 participants · Start Oct 2014 · Primary completion Feb 2019
Drug: DLBS3233; Metformin XR and 2 more · For: Polycystic Ovary Syndrome (PCOS); Insulin Resistance
Sites: Banjarmasin, Indonesia; Denpasar, Indonesia; Makasar, Indonesia · 7 sites in all
- Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)Pivotal-lookingCompleted
Dexa Medica GroupIndustry
NCT01733459 · 124 participants · Start Mar 2013 · Primary completion Apr 2018
Drug: DLBS3233; Metformin XR and 2 more · For: Polycystic Ovary Syndrome (PCOS)
Sites: Bandung, Indonesia; Jakarta, Indonesia
- The Efficacy and Safety of DLBS3233 in Adults With PrediabetesPivotal-lookingCompleted
Dexa Medica GroupIndustry
NCT07937449 · 120 participants · Start Jul 7, 2025 · Primary completion Oct 15, 2026
Drug: DLBS3233; Metformin XR · For: Prediabetes
Sites: Surabaya, Indonesia; Jakarta, Indonesia
- Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes MellitusPivotal-lookingCompleted
Dexa Medica GroupIndustry
NCT01645332 · 104 participants · Start Jul 2012 · Primary completion Aug 2014
Drug: Placebo of DLBS3233; DLBS3233 · For: Type-2-diabetes Mellitus; New Onset
Sites: Semarang, Indonesia
- Efficacy and Safety of DLBS3233 in Prediabetic PatientsPivotal-lookingCompleted
Dexa Medica GroupIndustry
NCT01531933 · 80 participants · Start Nov 2011 · Primary completion Jul 2012
Drug: DLBS3233; Placebo of DLBS3233 · For: Prediabetic
Sites: Padang, Indonesia
- Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes MellitusPivotal-lookingCompleted
Dexa Medica GroupIndustry
NCT01472614 · 54 participants · Start Sep 2011 · Primary completion Jan 2013
Drug: DLBS3233 · For: Type-2 Diabetes Mellitus
Sites: Surabaya, Indonesia · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The Efficacy and Safety of DLBS3233, A Combined Bioactive Fraction of Cinnamomum burmanii and Lagerstroemia speciosa Plants on The Endocrine-Metabolic Profile of Women with Polycystic Ovary Syndrome: A Randomized Clinical Trial.
Hestiantoro A, Permadi W, Tjandrawinata RR, et al. · Int J Fertil Steril 2024
- Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical Trial.
Nugroho H, Nurmilawati N, Novitasari D, et al. · Acta Med Indones 2024
- DLBS3233 enhances nephrin and podocin expression also reduces oxidative stress marker and insulin receptor serine diabetic rats' podocytes.
Mohani CI, Rudijanto A, Aulanni'am A, et al. · Ann Med Surg (Lond) 2023
- The Effect and Safety Assessment of Metformin and DLBS3233 (A Bioactive Fraction of Lagerstroemia speciosa and Cinnamomum burmannii) on Improving Metabolic Parameters in Women with Polycystic Ovary Syndrome.
Hidayat ST, Mulyantoro I, Damas S, et al. · Int J Womens Health 2023
- Administration of Cinnamon and Lagersroemia speciosa Extract on Lipid Profile of Polycystic Ovarian Syndrome Women with High Body Mass Index.
Permadi W, Hestiantoro A, Ritonga MA, et al. · J Hum Reprod Sci 2021
- Simultaneous micronization and purification of bioactive fraction by supercritical antisolvent technology.
Hiendrawan S, Veriansyah B, Widjojokusumo E, et al. · J Adv Pharm Technol Res 2017
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.